OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml
Details
- Manufacturer
- Merck (Schweiz) AG
- ATC code
- G03GA08
- Status
- 9 abgeschlossen
- Reported since
- 20 days
- First report
- 05.05.2023
- Active substance
- choriogonadotropinum alfa
- Swissmedic no.
- 5636401
- Public price (PPUB)
- CHF 49.85
- Ex-factory price (PEXF)
- CHF 30.74
- Product information (AIPS)
- swissmedicinfo.ch →
Overview
OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml is a medication by Merck (Schweiz) AG containing the active substance choriogonadotropinum alfa (ATC code G03GA08). This entry is marked as resolved — the documented shortage lasted 20 days. This is the only product approved in Switzerland with this active substance.
Available alternatives
No alternatives with the same active substance are currently available.
Composition
choriogonadotropinum alfa 250 µg, poloxamerum 188, mannitolum, acidum phosphoricum concentratum, natrii hydroxidum corresp. natrium 0.1 mg, methioninum, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml.
Frequently asked questions
What can I do if OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml is unavailable?▾
Contact your pharmacy or treating physician. Substitution with a product containing the same active substance (choriogonadotropinum alfa) is often possible. Available alternatives are listed above on this page.
What alternatives exist for OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml?▾
Available alternatives with the same active substance are listed above. choriogonadotropinum alfa is the underlying active substance — pharmacies can dispense a generic or alternative brand after consulting with the doctor.
When will OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml be available again?▾
The expected delivery date — if communicated by the manufacturer — is shown in the detail section on this page. Shortages in this active-substance class typically last several weeks in Switzerland. Only the manufacturer can provide a binding forecast.
Why is OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml unavailable?▾
Common reasons include manufacturing problems, active-substance shortages, quality issues, or a planned withdrawal from the Swiss market. More detailed background — when disclosed by the manufacturer — is shown in the detail section above.
Where do I report a shortage of OVITRELLE Inj Lös 250 mcg/0.5 ml Fertspr 0.5 ml?▾
Shortages are officially reported to drugshortage.ch (by manufacturers and pharmacies). Patients and treating physicians can escalate the shortage through their pharmacy — which has direct access to the reporting pipeline.
Source: drugshortage.ch · no warranty of completeness